Renaissance Technologies (RenTech)'s BMRN Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 1.32 M shares of BioMarin Pharmaceutical Inc. (BMRN) worth $78.74 M, representing 0.12% of the portfolio. First purchased in 2013-Q4, this long-term strategic position has been held for 42 quarters.
Based on 13F filings since 2013, Renaissance Technologies (RenTech) has maintained a long-term strategic position in BMRN, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2025, adding 911,000 shares. Largest reduction occurred in Q4 2025, reducing 568,600 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s BioMarin Pharmaceutical (BMRN) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioMarin Pharmaceutical (BMRN) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -568,600 | Reduce 30.03% | 1.32 M | $59.43 |
| Q3 2025 | +86,800 | Add 4.80% | 1.89 M | $54.16 |
| Q2 2025 | +911,000 | Add 101.70% | 1.81 M | $54.97 |
| Q1 2025 | +459,900 | Add 105.51% | 895,771 | $70.69 |
| Q4 2024 | +17,000 | Add 4.06% | 435,871 | $65.73 |
| Q3 2024 | +302,671 | Add 260.47% | 418,871 | $70.29 |
| Q2 2024 | -425,871 | Reduce 78.56% | 116,200 | $82.33 |
| Q1 2024 | +155,400 | Add 40.19% | 542,071 | $87.34 |
| Q4 2023 | -195,100 | Reduce 33.54% | 386,671 | $96.42 |
| Q3 2023 | -150,867 | Reduce 20.59% | 581,771 | $88.48 |
| Q2 2023 | -48,433 | Reduce 6.20% | 732,638 | $0.09 |
| Q1 2023 | +150,800 | Add 23.93% | 781,071 | $0.10 |
| Q4 2022 | -114,200 | Reduce 15.34% | 630,271 | $0.10 |
| Q3 2022 | +9,708 | Add 1.32% | 744,471 | $84.77 |
| Q2 2022 | +243,592 | Add 49.59% | 734,763 | $82.87 |
| Q1 2022 | -159,889 | Reduce 24.56% | 491,171 | $77.10 |
| Q4 2021 | +269,589 | Add 70.67% | 651,060 | $88.35 |
| Q3 2021 | +91,500 | Add 31.55% | 381,471 | $77.29 |
| Q2 2021 | -75,600 | Reduce 20.68% | 289,971 | $83.44 |
| Q1 2021 | +365,571 | New Buy | 365,571 | $75.51 |
| Q2 2020 | -19,100 | Sold Out | 0 | $0.00 |
| Q1 2020 | -183,371 | Reduce 90.57% | 19,100 | $84.50 |
| Q4 2019 | -353,600 | Reduce 63.59% | 202,471 | $84.55 |
| Q3 2019 | +18,700 | Add 3.48% | 556,071 | $67.40 |
| Q2 2019 | +215,400 | Add 66.90% | 537,371 | $85.65 |
| Q1 2019 | +278,400 | Add 638.96% | 321,971 | $88.83 |
| Q4 2018 | -163,400 | Reduce 78.95% | 43,571 | $85.15 |
| Q3 2018 | +178,500 | Add 626.95% | 206,971 | $96.97 |
| Q2 2018 | -100,100 | Reduce 77.86% | 28,471 | $94.20 |
| Q1 2018 | -132,800 | Reduce 50.81% | 128,571 | $81.07 |
| Q4 2017 | -58,900 | Reduce 18.39% | 261,371 | $89.17 |
| Q3 2017 | +193,400 | Add 152.44% | 320,271 | $93.07 |
| Q2 2017 | +126,871 | New Buy | 126,871 | $90.82 |
| Q1 2017 | -39,371 | Sold Out | 0 | $0.00 |
| Q4 2016 | +39,371 | New Buy | 39,371 | $82.83 |
| Q2 2016 | -132,071 | Sold Out | 0 | $0.00 |
| Q1 2016 | -61,500 | Reduce 31.77% | 132,071 | $82.48 |
| Q4 2015 | -69,000 | Reduce 26.28% | 193,571 | $104.76 |
| Q3 2015 | +138,900 | Add 112.31% | 262,571 | $105.32 |
| Q2 2015 | +123,671 | New Buy | 123,671 | $136.78 |
| Q1 2014 | -280,071 | Sold Out | 0 | $0.00 |
| Q4 2013 | +280,071 | New Buy | 280,071 | $70.35 |
Renaissance Technologies (RenTech)'s BioMarin Pharmaceutical Investment FAQs
Renaissance Technologies (RenTech) first purchased BioMarin Pharmaceutical Inc. (BMRN) in Q4 2013, acquiring 280,071 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held BioMarin Pharmaceutical Inc. (BMRN) for 42 quarters since Q4 2013.
Renaissance Technologies (RenTech)'s largest addition to BioMarin Pharmaceutical Inc. (BMRN) was in Q2 2025, adding 1,806,771 shares worth $99.32 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 1,324,971 shares of BioMarin Pharmaceutical Inc. (BMRN), valued at approximately $78.74 M.
As of the Q4 2025 filing, BioMarin Pharmaceutical Inc. (BMRN) represents approximately 0.12% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in BioMarin Pharmaceutical Inc. (BMRN) was 1,893,571 shares, as reported at the end of Q3 2025.